Hospital for Special Surgery
New York, 10021, United States
NCT Number: NCT00990288
The purpose of this study is to determine if the agent, Floseal, can decrease the amount of blood patients lose after total knee replacement (TKR) surgery. If this product can be found to have an effect on bleeding, it may potentially reduce the problems associated with bleeding after knee replacement surgery such as pain, stiffness, and the need to have a blood transfusion. The subject's overall participation will be over a period of 6 weeks.
Looking for future studies?
Notify MeAll sexes
Interventional
Phase 4
New York, 10021, United States
This is a prospective double blind randomized clinical trial of patients requiring unilateral total knee arthroplasty. The patients will be randomized intra-operatively to receiving Floseal or no treatment.
Both the patient and the observers will be blinded to whether the subject received Floseal or no treatment. Only the operating surgeons will be aware of whether Floseal or no treatment was given.
As was performed in the pilot study, randomization of Floseal or no treatment will be performed using the sealed envelope technique. Randomization will occur at the time of surgery. The statistician is responsible for maintaining the randomization schedule and issuing the sealed envelopes. The inner envelope will contain whether Floseal or no treatment is to be given on a card which will be counter-signed by the surgeon at the time of surgery. The inner envelope will then be sealed, followed by sealing of the outer envelope. Following the procedure, the surgeon will then take the sealed and signed envelope to surgeon who will store and file it in a locked cabinet in his office. The patients study number will be on the outside surface of the envelopes.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
FloSeal will be administered following the cementing of all knee components. Prior to release of the tourniquet and after the cement has cured, it will be applied to cut, exposed bone ends as well as the intra-articular soft tissues by the use of a delivery syringe, Direct manual pressure with a gauze sponge will be applied following its application for 2 minutes, ensuring that it adheres to the bleeding bone surface.
Other names: "FloSeal", a thrombin and collagen based agent
Time frame: preoperatively and on the day of surgery
Time frame: preoperatively and day of surgery
Time frame: preoperatively and one day after surgery
Time frame: preoperatively and 1 day after surgery
Time frame: preoperatively and two days after surgery
Time frame: preoperatively and two days after surgery
Time frame: 24 hours postoperatively
Time frame: three days postoperatively
Time frame: three days postoperatively
Time frame: 3days postoperatively
Time frame: 3 days postoperatively
A VAS is a measurement instrument that tries to measure a characteristic or attitude that cannot easily be measured.
The pain VAS scale measures pain intensity on a scale of 0 to 10, with 0=no pain. A higher score indicates greater pain intensity.
Time frame: 6 weeks postoperatively
Time frame: 6 weeks postoperatively
A VAS is a measurement instrument that tries to measure a characteristic or attitude that cannot easily be measured.
The pain VAS scale measures pain intensity on a scale of 0 to 10, with 0=no pain. A higher score indicates greater pain intensity.
Hospital for Special Surgery, New York
Other
The Role of a Topical Hemostatic Agent in Reducing Blood Loss in Unilateral Total Knee Arthroplasty
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05980013
Blood Loss, Fluid Loss
Denver, Colorado, United States
View Trial DetailsNCT06855472
Blood Loss, Hemorrhage
Ankara, Turkey (Türkiye)
View Trial DetailsNCT04089865
Blood Loss, Blood Transfusion
New York, United States
View Trial DetailsNCT03249038
Blood Loss, Blood Loss, Postoperative
View Trial Details